This interaction activates the STAT3 signaling pathway, upregulating immunosuppressive molecules such as FOXP3, CD39, and IL‐10, while promoting the recruitment of peripheral Tregs to tumor sites and facilitating the conversion of CD4+ T cells into Tregs. The gene discussed is ENTPD1; the disease is neoplasm.